Liprolog Junior Kwikpen (Insulin Lispro)

Insulin lispro is a rapid‑acting insulin analog that provides post‑prandial glucose control in diabetes mellitus.

• Type 1 diabetes mellitus: rapidly reduces post‑meal blood glucose spikes.
• Type 2 diabetes mellitus: assists in achieving glycaemic targets when combined with oral agents or basal insulin.
• Diabetes mellitus (general): offers flexible dosing for mealtime insulin needs.

• Insulin lispro binds to the insulin receptor on cell membranes, activating the receptor’s tyrosine kinase activity. This triggers intracellular signaling cascades that promote translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake in muscle and adipose tissue and suppressing hepatic glucose production, thereby lowering circulating blood glucose levels.

Insulin lispro may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Hypoglycaemia: low blood glucose episodes, especially if meals are missed.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Lipodystrophy: localized changes in subcutaneous fat with repeated injections.
• Weight gain: modest increase associated with improved glycaemic control.

Serious or Rare Side Effects

• Severe hypoglycaemia: neuroglycopenic symptoms requiring assistance.
• Allergic reactions: urticaria, angio‑edema, or anaphylaxis.
• Hypokalemia: low serum potassium levels, particularly with high insulin doses.
• Persistent hyperglycaemia: may indicate insulin resistance or dosing error.

When using insulin lispro, consider the following safety measures.

• Blood glucose monitoring: check levels before meals and at bedtime to adjust dose.
• Hypoglycaemia risk: avoid dosing if blood glucose is already low; have fast‑acting carbohydrate available.
• Concomitant medications: adjust insulin when using glucocorticoids or other agents that raise glucose.
• Renal or hepatic impairment: start with lower doses and titrate cautiously.
• Pregnancy and lactation: use only if benefits outweigh potential risks, as data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro can interact with several drug classes, affecting glucose control.

Major Interactions (Avoid)

• Sulfonylureas or meglitinides: combined use may cause severe hypoglycaemia.
• Alcohol: can potentiate insulin’s glucose‑lowering effect and mask hypoglycaemia symptoms.
• Beta‑blockers: may blunt hypoglycaemia warning signs.

Moderate Interactions (Monitor Closely)

• Corticosteroids: increase insulin resistance, requiring dose adjustments.
• Thiazide diuretics: may raise blood glucose, necessitating closer monitoring.
• ACE inhibitors or ARBs: can enhance insulin sensitivity, potentially lowering required insulin dose.